Millions of obese Americans would get access to popular weekly injectables that would help them shed pounds quickly if a $35 ...

There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

The plan would need to be supported by the incoming Trump administration, which has vowed to cut costs across the federal ...

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

About 42% of U.S. adults are obese, the CDC says. GLP-1 medications have changed the picture for people hoping to reduce ...

Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by ...

The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.

Share on Facebook Share on Twitter Under a new rule the Biden administration proposed on Tuesday, millions of Americans with ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

The Biden administration has announced a new proposal to include weight-loss drugs under Medicare and Medicaid programmes. While the plan will help more than seven million Americans struggling with ...

The Biden administration is looking to extend Medicare and Medicaid coverage to include obesity drugs like Wegovy and Zepbound. Weight loss drugs are now excluded from mandatory coverage.